Summary of international expert votes on the importance of various clinical and laboratory outcome variables to measuring disease activity in sJIA.
| No. Votes | Outcome Variable |
|---|---|
| 141 | No. joints with active arthritis by physician assessment |
| 109 | No. days of fever in the last 2 weeks |
| 92 | Erythrocyte sedimentation rate |
| 92 | Patient’s global assessment of disease activity |
| 75 | Parent’s global assessment of disease activity |
| 74 | sJIA rash by physician examination |
| 71 | C-reactive protein |
| 65 | Hemoglobin |
| 53 | No. min with morning stiffness in the last 2 weeks |
| 51 | Platelet count |
| 49 | No. swollen joints by physician assessment |
| 49 | Increased or new medications |
| 48 | CHAQ overall score |
| 46 | Parent’s global measure of severity |
| 39 | Ferritin |
| 37 | sJIA rash by patient history |
| 35 | Splenomegaly |
| 34 | Albumin |
| 33 | Hepatomegaly |
| 29 | Discontinued/added/changed medications |
| 28 | No. joints with decreased range of motion by physician assessment |
| 28 | White blood cell count |
| 26 | Parent’s global measure of impact |
| 18 | Lymphadenopathy |
| 17 | Patient-rated quality of life |
| 16 | Neutrophil count |
| 14 | Patient’s global measure of overall pain |
| 10 | D-dimer |
| 10 | Tenosynovitis |
| 8 | Patient’s global measure of joint pain |
| 7 | Parent’s global measure of pain |
| 6 | Patient-related fatigue |
| 4 | Chest pain by patient history |
| 3 | Decrease in physical activity level as indicated by patient |
| 3 | Reduction of height velocity |
| 1 | Alanine transaminase |
| 1 | No. days with a sore throat in the last 2 weeks |
| 0 | Aspartate transaminase |
| 0 | Mean cell volume |
| 0 | Patient’s global measure of muscle pain |
sJIA: systemic juvenile idiopathic arthritis; CHAQ: Childhood Health Assessment Questionnaire.